ZY OG1
Alternative Names: ZY-OG1Latest Information Update: 11 Jul 2016
At a glance
- Originator Zydus Cadila
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 11 Jul 2016 Discontinued - Phase-I for Obesity (In volunteers) in India (PO)
- 11 Jul 2016 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in India (PO)
- 08 Sep 2010 Phase-I clinical trials in Obesity (in volunteers) in India (PO) (CTRI2010-091-000684)